This is a non-core endpoint: only basic statistics are computed.
See its core counterpart C3_THYMUS_EXALLC for full statistics.
Malignant neoplasm of thymus
C3_THYMUS
thymus neoplasm: A neoplasm that affects the thymus. Representative examples include thymoma and carcinoma.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
112 |
4. Check minimum number of eventsNone |
112 |
5. Include endpointsNone |
112 |
6. Filter based on genotype QC (FinnGen only) |
112 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF9
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of thymus
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of thymus, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm of respiratory system and intrathoracic organs
- Malignant neoplasm of respiratory system and intrathoracic organs, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm
- Any event in cancer register
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 112 | 51 | 61 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.03 |
| Median age at first event (years) | 60.78 | 58.59 | 62.60 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 99
- Matched controls
- 989
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D38.3
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Mediastinum
+∞
52.9
46
*
C37
ICD-10 Finland
Malignant neoplasm of thymus
+∞
46.6
41
*
GEC24
NOMESCO Finland
Thoracoscopic thymectomy
+∞
45.3
40
*
D38.4
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Thymus
+∞
44.1
39
*
8580/3-C37.9
ICD-O-3
Thymoma, NOS, of thymus
+∞
32.0
29
*
D15.0
ICD-10 Finland
Benign neoplasm: Thymus
+∞
32.0
29
*
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
32.9
29.6
39
19
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
13.3
23.5
45
58
GEC23
NOMESCO Finland
Transsternal thymectomy
+∞
20.5
19
*
8582/3-C37.9
ICD-O-3
Thymoma, type AB of thymus
+∞
19.4
18
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
6.4
16.1
74
311
WX408
NOMESCO Finland
General anesthesy, balanced
5.8
14.4
53
164
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
7.7
14.2
36
68
G70.0
ICD-10 Finland
Myasthenia gravis
+∞
13.9
13
*
GD1AD
NOMESCO Finland
Thorax CT examination
12.0
13.5
25
27
GEB30
NOMESCO Finland
Mediastinotomy and excision of lesion
+∞
12.8
12
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
21.6
12.6
18
10
N07AA02
ATC
pyridostigmine; systemic
+∞
11.7
11
*
H02AB02
ATC
dexamethasone; systemic
6.9
10.8
28
53
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
11.1
10.6
20
22
ZXC96
NOMESCO Finland
Robot assisted procedure
15.5
10.6
17
13
108
Kela drug reimbursment
Myasthenia gravis
+∞
10.6
10
*
WF004
NOMESCO Finland
Palliative radiotherapy
33.7
9.6
12
*
130
Kela drug reimbursment
Malignant tumour
7.0
9.5
24
43
A03FA01
ATC
metoclopramide; systemic, rectal
4.6
9.2
36
109
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
11.1
9.2
17
18
GD5BD
NOMESCO Finland
Thorax and upper abdomen combined extensive CT examination of
12.5
9.2
16
15
R4110
NOMESCO Finland
Physiotherapy
4.1
9.2
43
155
JN4BD
NOMESCO Finland
Extensive body CT
5.5
9.0
28
66
B01AB05
ATC
enoxaparin; parenteral
3.8
8.7
47
189
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
49.0
7.8
9
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
11.4
7.8
14
14
WX302
NOMESCO Finland
Thoracal epidural anesthesy
8.9
7.8
16
21
D38.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Trachea, bronchus and lung
12.3
7.6
13
12
8585/3-C37.9
ICD-O-3
Thymoma, type B3 of thymus
+∞
7.4
7
*
8583/3-C37.9
ICD-O-3
Thymoma, type B1 of thymus
+∞
7.4
7
*
8581/3-C37.9
ICD-O-3
Thymoma, type A of thymus
+∞
7.4
7
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
10.0
7.3
14
16
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
8.9
6.9
14
18
WF002
NOMESCO Finland
Radical radiotherapy
7.8
6.8
15
22
ZX070
NOMESCO Finland
Intensity modified radiotherapy
13.6
6.8
11
9
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
6.0
6.7
18
35
JN6AD
NOMESCO Finland
CT of torso and neck
28.7
6.3
8
*
XX3DW
NOMESCO Finland
Time consuming IT work
4.6
6.3
22
58
D15.2
ICD-10 Finland
Benign neoplasm: Mediastinum
+∞
6.3
6
*
C38.1
ICD-10 Finland
Malignant neoplasm: Anterior mediastinum
+∞
6.3
6
*
8070/3-C37.9
ICD-O-3
Squamous cell carcinoma, NOS, of thymus
+∞
6.3
6
*
A04AA02
ATC
granisetron; systemic, transdermal
7.6
6.3
14
21
UGC12
NOMESCO Finland
Flexible bronchoscopy
5.2
6.3
19
43
GD1CT
NOMESCO Finland
Biopsy of the lung with CT guidance
13.7
6.2
10
8
WX402
NOMESCO Finland
General anaesthesia
3.8
6.2
28
94
Z51.5
ICD-10 Finland
Palliative care
8.9
6.0
12
15
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
65
212
5.92
19.99
2.6
2.3
—
—
—
0
0
14
10
15.86
15.32
5.4
3.7
4.5
3.7
nmol/l
—
14
10
99
537
8.27
15.14
18.3
9.5
4.0
4.1
e9/l
0.23
87
473
87
445
5.28
13.63
5.3
4.2
—
—
—
0
0
84
426
4.89
13.10
12.3
7.1
1.2
1.2
mmol/l
0.06
75
364
37
114
4.35
11.23
10.8
5.6
104.2
103.5
mmol/l
0.36
37
109
12
12
11.08
10.63
3.2
1.7
28.0
18.1
ug/l
0.44
12
12
23
52
5.31
10.09
10.1
5.1
25.4
24.8
mmol/l
0.30
23
52
34
107
4.13
9.92
11.6
6.3
13.9
11.9
kpa
0.83
34
102
34
107
4.13
9.92
11.6
6.3
5.4
5.1
kpa
1.21
34
101
66
325
3.51
9.75
3.6
3.0
—
—
—
0
0
15
23
7.38
9.61
1.5
1.1
—
—
—
0
0
15
26
6.51
8.58
2.3
1.9
242.1
179.4
%
1.56
15
26
54
254
3.17
8.27
3.3
3.0
0.2
0.4
e6/l
1.00
43
183
36
139
3.34
7.57
3.4
2.8
2.9
1.7
e6/l
0.19
23
75
43
186
3.13
7.48
1.8
1.9
2.8
2.9
mg/l
0.10
38
161
37
151
3.17
7.05
3.4
2.7
1.9
0.7
e6/l
0.60
24
86
9
7
13.83
5.68
1.1
1.3
—
—
—
0
0
41
200
2.66
5.47
2.0
1.7
1.4
1.2
mg/l
0.31
33
161
35
164
2.65
5.00
2.6
3.2
42.3
138.6
ng/l
1.22
28
128
27
114
2.80
4.69
2.1
2.5
23.5
24.4
%
0.11
27
100
24
104
2.66
3.93
2.3
4.4
1.9
12.5
ug/l
1.49
16
83
8
11
7.73
3.93
1.0
1.2
—
—
—
0
0
9
15
6.42
3.90
1.3
1.3
—
—
—
0
0
9
17
5.65
3.59
1.0
1.3
—
—
—
0
0
12
39
3.33
3.19
3.8
2.0
39.4
42.0
u/l
0.17
12
32
6
8
7.84
3.09
1.3
1.3
—
—
—
0
0
5
6
8.64
2.77
1.0
1.5
—
—
—
0
0
10
32
3.33
2.72
3.1
2.9
—
—
—
0
0
7
15
4.90
2.64
1.4
1.4
—
—
—
0
0
26
143
2.07
2.46
1.7
1.8
—
—
—
0
0
13
53
2.64
2.37
3.0
2.4
208.4
102.6
ng/l
1.06
13
46
8
23
3.66
2.32
1.9
1.4
—
—
—
0
0
8
23
3.66
2.32
1.1
1.5
—
—
—
0
0
6
13
4.81
2.30
2.3
3.5
21.5
16.9
u/ml
—
6
13
6
13
4.81
2.30
2.7
3.2
—
—
—
0
0
11
42
2.80
2.26
1.5
2.1
2.0
1.7
g/l
0.35
11
36
5
9
5.75
2.23
1.0
1.0
—
—
—
0
0
26
149
1.97
2.19
1.3
1.2
14.7
27.7
iu/ml
—
6
53
14
62
2.44
2.18
1.8
1.3
—
—
—
0
0
14
63
2.40
2.11
6.4
4.5
74.0
84.4
ng/l
0.34
14
57
5
10
5.17
2.09
2.4
1.5
—
—
—
0
0
8
26
3.23
2.05
4.5
1.1
0.0
0.0
g/l
—
8
26
8
26
3.23
2.05
4.5
1.1
0.0
0.0
g/l
—
8
26
6
16
3.90
1.96
1.5
1.4
—
—
—
0
0
8
29
2.89
1.83
4.5
1.1
0.1
0.0
g/l
—
8
29
9
36
2.63
1.78
4.1
1.2
—
—
—
0
0
6
18
3.46
1.77
1.8
2.7
3.7
3.5
u/ml
—
6
18
8
30
2.79
1.76
2.0
1.5
—
—
—
0
0
8
30
2.79
1.76
1.8
2.0
—
—
—
0
0
78
645
1.69
1.75
2.9
3.1
55.4
55.4
u/l
0.00
73
611
10
43
2.46
1.65
1.2
1.4
—
—
—
0
0
15
78
2.07
1.63
4.0
3.2
83.1
64.4
ml/min/173m2
—
8
34
16
87
1.98
1.55
2.1
2.1
27.6
34.7
u/l
0.69
16
68
48
365
1.55
1.44
4.0
3.5
57.6
36.8
ng/l
0.30
42
254
6
23
2.70
1.38
1.5
1.6
—
—
—
0
0
18
107
1.81
1.36
2.3
2.5
8.8
11.2
umol/l
0.21
18
95
17
101
1.81
1.28
1.5
1.7
—
—
—
0
0
5
19
2.70
1.23
1.0
1.4
—
—
—
0
0
6
26
2.38
1.20
1.5
1.6
—
—
—
0
0
12
65
1.95
1.18
4.3
6.9
25.4
24.7
mmol/l
0.39
12
60
98
900
1.71
1.06
4.0
4.4
5.7
6.0
mmol/l
1.38
92
830
7
34
2.13
1.05
1.3
1.4
48.0
26.3
iu/l
—
7
34
13
76
1.80
1.04
3.9
2.2
330.2
375.3
nmol/l
0.51
13
69
38
295
1.44
0.97
3.1
2.7
65.8
55.5
u/l
0.58
38
277
15
94
1.69
0.96
2.6
3.3
—
—
—
0
0
56
467
1.40
0.96
4.2
4.7
0.0
0.0
estimate
0.00
11
87
20
136
1.57
0.95
1.1
1.5
—
—
—
0
0
88
947
0.67
0.88
4.1
4.9
2.8
2.8
mmol/l
0.06
83
875
16
105
1.61
0.87
1.7
1.7
—
—
—
0
0
6
31
1.99
0.86
1.7
1.7
—
—
—
0
0
87
935
0.69
0.81
3.6
4.4
4.8
4.7
mmol/l
0.36
82
868
0
24
0.00
0.80
0.0
2.0
—
133.2
—
0
14
0
24
0.00
0.80
0.0
1.3
—
—
—
0
0
5
23
2.23
0.77
1.6
2.2
—
—
—
0
0
55
471
1.33
0.74
3.0
3.5
0.0
0.0
estimate
0.00
11
82
20
150
1.41
0.61
1.2
1.3
1.0
6.9
u/ml
—
5
65
74
673
1.29
0.59
3.3
3.7
14.9
14.8
pmol/l
0.08
68
607
88
932
0.74
0.57
3.6
4.4
1.4
1.4
mmol/l
0.01
83
858
85
904
0.75
0.57
3.2
3.9
1.3
1.3
mmol/l
0.26
80
831
39
330
1.28
0.55
1.7
1.8
89.5
94.0
pmol/l
0.31
26
159
10
66
1.57
0.54
1.6
1.6
—
—
—
0
0
53
467
1.26
0.53
3.1
3.5
0.0
0.0
estimate
—
10
88
7
50
1.43
0.46
1.0
1.0
—
—
—
0
0
0
19
0.00
0.39
0.0
1.1
—
—
—
0
0
28
316
0.85
0.27
4.3
4.4
20.5
22.3
%
0.40
16
156
0
11
0.00
0.21
0.0
2.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
548.2
—
0
5
0
10
0.00
0.21
0.0
1.0
—
32.3
—
0
5
6
50
1.21
0.20
1.0
2.4
1.2
1.2
%
—
6
50
8
72
1.12
0.16
4.0
4.0
1.2
1.2
mmol/l
—
8
66
10
119
0.82
0.16
1.7
1.4
—
—
—
0
0
7
85
0.81
0.15
1.1
1.7
—
—
—
0
0
5
48
1.04
0.09
2.8
3.6
4.0
4.6
pmol/l
—
5
43
36
375
0.94
0.07
3.2
3.5
—
—
—
0
0
59
577
1.05
0.05
2.8
2.9
—
—
—
0
0
25
260
0.95
0.03
3.7
3.6
0.0
0.0
estimate
—
8
83
23
223
1.04
0.01
3.7
2.8
0.9
0.7
ug/l
0.39
17
151
11
116
0.94
0.01
17.3
8.2
—
—
—
0
0
11
105
1.05
0.00
2.5
1.7
—
—
—
0
0
0
8
0.00
0.00
0.0
4.6
—
—
—
0
0
0
8
0.00
0.00
0.0
4.6
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
9
98
0.91
0.00
2.2
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
91.5
—
0
6
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
2.9
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_THYMUS – Malignant neoplasm of thymus
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).